PDF Mitochondrial division inhibitor 1 a promising therapeutic Biology Diagrams The regulation of mitotic slippage in cells treated with microtubule/spindle poisons. The top panel shows a cell undergoing normal mitosis. Both APC/C and CRL2 ZYG11A/B ubiquitin ligases target the degradation of the mitotic regulator cyclin B1 to allow cells to progress from metaphase to anaphase and undergo mitotic exit. The middle panel shows a cell treated with an antimicrotubule drug that
Highly selective inhibitors developed against these targets showed robust cytotoxic activity in preclinical models. Similar to MT poisons, these anti-mitotics cause drug-specific and dose-dependent mitotic phenotypes through disruption of mitotic spindle morphology and MT-chromosome attachment or impairment of SAC (figure, bottom).
Addressing a weakness of anticancer therapy with mitosis inhibitors ... Biology Diagrams
Mitotic inhibitors bind to tubulin and inhibit its polymerization into microtubules. Microtubules are structures responsible for pulling the cell apart when it divides. Mitotic inhibitors affect cancer cells more than normal cells because cancer cells divide (mitotic cell division) more rapidly therefore are more susceptible to mitotic inhibition. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res 2010; 70 : 10255-10264. Article CAS PubMed Google Scholar
Functional redundancy between mitotic kinesins could be amongst the reasons that challenge the clinical efficacy of Eg5 inhibitors [59]. Interestingly, these Eg5 inhibitors induce cell death in combination with taxol even in taxol-resistant cancer cells, highlighting the therapeutic potential of Eg5 inhibition in combination with other
Anti-mitotic therapies in cancer Biology Diagrams
The development of mitotic kinase inhibitors came as an outgrowth of studies on the molecular mechanisms of the cell cycle in the 1990s [38-40], which promised the development of precise inhibitors of mitosis without the toxic sequelae of classical chemotherapeutics. Yet for all the initial excitement, mitotic kinase inhibitors have now been
